Exploring new treatments for breast and ovarian cancer using epigenetic therapy and PARP inhibitors
Linking Epigenetic-Therapy Induction of Inflammasome Signaling to Generation of a BRCAness Phenotype
This study is looking at how a new combination of cancer treatments might work better for people with breast and ovarian cancer, even if they don't have a specific gene mutation, by boosting the body's immune response to help the therapy be more effective.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Coriell Institute for Medical Research NIH-funded |
| Lab location | 1 site (Camden, United States) |
| Project ID | NIH-10886791 on NIH RePORTER |
What this research studies
This research investigates how combining a hypomethylating agent with a novel PARP inhibitor can enhance cancer treatment for patients with breast and ovarian cancer, regardless of their BRCA mutation status. The approach focuses on inducing inflammasome signaling to create a BRCAness phenotype, which may improve the effectiveness of the therapy. The study includes both preclinical and clinical phases, aiming to expand the benefits of PARP inhibitors to a broader patient population. Patients will be monitored through correlative analyses of serial samples to understand the mechanisms behind treatment responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with breast or ovarian cancer, particularly those with triple-negative breast cancer or those who are BRCA proficient.
Not a fit: Patients with cancers that are not breast or ovarian, or those who have already exhausted all treatment options, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for breast and ovarian cancer patients who do not have BRCA mutations.
How similar studies have performed: Other research has shown promising results with similar approaches, particularly in enhancing the efficacy of PARP inhibitors in cancer treatment.
Where this research is happening
Camden, United States
- Coriell Institute for Medical Research — Camden, United States (Active)
Researchers
- Principal investigator: Nephew, Kenneth P — Coriell Institute for Medical Research
- Study coordinator: Nephew, Kenneth P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.